Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II MT-3724 Monotherapy Study in Relapsed and Refractory Diffuse-Large-B-Cell-Lymphoma Patients

Next Previous
Trial Profile

A Phase II MT-3724 Monotherapy Study in Relapsed and Refractory Diffuse-Large-B-Cell-Lymphoma Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MT 3724 (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Molecular Templates

    • Most Recent Events

    • 21 Nov 2019 According to an Molecular Templates media release, the company announces pricing of $50.0 million public equity offering. The company expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund this ongoing study.
    • 12 Aug 2019 According to a Molecular Templates media release, trial update is expected by the end of year.
    • 28 Mar 2019 According to a Molecular Templates media release, the phase II dose of 50 mcg/kg for this study was selected based on safety data, tumor responses observed at dose levels as low as 5 and 20 mcg/kg, and pharmacodynamic effects of CD20+ B-cell clearance observed at various doses in the phase I/Ib study (NCT02361346).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top